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###### Synopsis

The p.G991A variant of *PHKA2* could be a major cause of ketotic hypoglycemia in Japanese patients who do not have hepatomegaly or elevated liver enzymes.

1. INTRODUCTION {#jmd212041-sec-0003}
===============

Ketotic hypoglycemia (KH) is a major cause of hypoglycemia; it is responsible for 30%‐50% of cases of childhood hypoglycemia. However, the exact pathogenesis of KH is unknown. Consequently, a diagnosis of KH can be established only after eliminating other known diseases, including glycogen storage diseases (GSDs). Boys are more susceptible to KH than girls are.[1](#jmd212041-bib-0001){ref-type="ref"} In Japan, the prevalence in boys is twice that in girls.[2](#jmd212041-bib-0002){ref-type="ref"}

Glycogen storage disease type IXa (OMIM 306000) is a rare X chromosome‐linked disease. Most patients with GSD type IXa are boys. Patients usually present with fasting hypoglycemia, hepatomegaly, growth retardation, and mild elevation of transaminases. These symptoms disappear over time.

Brown et al.[1](#jmd212041-bib-0001){ref-type="ref"} performed genetic analyses of 164 children (96 boys, 68 girls) who had had two or more episodes of KH (blood glucose level \<50 mg/dL). The patients did not have hepatomegaly and did not seem to have GSDs. Nevertheless, variants in *PHKA2* were detected in 10 boys and 2 girls. This finding led us to hypothesize that unidentified *PHKA2* variants may be a major cause of childhood KH, and may explain the different incidences of KH in boys and in girls.

2. CASE {#jmd212041-sec-0004}
=======

A 4‐year‐old boy was referred to our hospital because of recurrent KH. He was born at full term and had a birth weight of 2940 g. At the age of 2 years and 7 months, the patient developed KH for the first time. When he was 4 years old, he suffered from recurrent hypoglycemia approximately every 2 months. The patient\'s hypoglycemic episodes mostly occurred in the morning within 12 hours from his last meal, even though he ate dinner as usual. In particular, the patient became hypoglycemic during infections. At the age of 4 years and 11 months, the patient was started on a bedtime uncooked cornstarch supplement to prevent nocturnal hypoglycemia. Since then, he has experienced no hypoglycemic episodes.

At the age of 5 years and 4 months, the patient\'s height was 113.0 cm (+0.9 SD) and his weight was 20.4 kg (+0.7 SD). Fasting for 14.5 hours induced hypoglycemia (Table [1](#jmd212041-tbl-0001){ref-type="table"}). Endocrinologic data, including thyroid‐stimulating hormone, growth hormone, adrenocorticotropic hormone, free triiodothyronine, free thyroxine, insulin, cortisol, epinephrine, norepinephrine, and dopamine, showed no abnormality. Urinary organic acid analysis and blood acylcarnitine analysis showed nonspecific profiles. During our investigations, the patient exhibited no signs of hepatomegaly, and the concentrations of transaminases in his serum were normal. The patient is currently 9 years old, and his physical and mental development is normal. Bedtime supplementation with uncooked cornstarch was stopped when the patient was aged 9 years and 1 month. The patient\'s elder sister has experienced no hypoglycemic episodes, and his 6‐year‐old brother has experienced KH only once. As far as we examined, there are no relatives who had experienced recurrent hypoglycemia.

###### 

Results of the fasting test

  Fasting time   Blood glucose (mM)   Free fatty acid (μM)   β‐hydroxybutyrate (μM)   Acetoacetate (μM)   Lactate (mM)   Alanine (nmol/mL)
  -------------- -------------------- ---------------------- ------------------------ ------------------- -------------- -------------------
  0 h            7.16                 196                    20                       41                  0.83           264
  14.5 h         2.89                 3020                   996                      445                 0.67           122

*Note*: Free fatty acid, β‐hydroxybutyrate, and acetoacetate levels were measured in serum. Lactate was measured after removing protein from the blood.

3. METHODS {#jmd212041-sec-0005}
==========

3.1. Gene panel analysis {#jmd212041-sec-0006}
------------------------

Using the MiSeq Sequencing System (Illumina, San Diego, CA) at the Kazusa DNA Research Institute, we performed mutation analysis using a DNA panel consisting of 59 genes (including *GYS2*, *PHKA2*, *PHKB*, *PHKG2*, *PYGL*, *ACAT1*, *OXCT1*, and *SLC16A1*) suspected to be involved in fatty acid oxidation, ketone body metabolism and transport, or GSDs.

3.2. Enzyme assays {#jmd212041-sec-0007}
------------------

Hemolysate from the patient was prepared by the method of Beutler et al.[3](#jmd212041-bib-0003){ref-type="ref"} Phosphorylase *b* kinase (PhK) activity was measured at pH 6.8 using exogenously applied phosphorylase *b* as a substrate following the method of Lederer with minor modification.[4](#jmd212041-bib-0004){ref-type="ref"} To summarize, 50 μL hemolysate was incubated at 37 °C in a final volume of 160 μL containing 6 mM ATP, 10 mM magnesium acetate, 5.6 units rabbit muscle phosphorylase *b*, 50 mM Tris‐HCl (pH 6.8), and 50 mM β‐glycerophosphate. At various time intervals, 20‐μL samples of the incubation mixture were removed and mixed with 150 μL of a cold solution of 5 mM EDTA, 0.1 M NaF, and 40 mM β‐glycerophosphate (pH 6.8); 20 μL of this mixture was used for the phosphorylase *a* assay. The PhK activity was calculated from the phosphorylase *a* activity. The thermal stability of PhK was studied by incubating the hemolysate at 45 °C for up to 30 minutes.[5](#jmd212041-bib-0005){ref-type="ref"}, [6](#jmd212041-bib-0006){ref-type="ref"}, [7](#jmd212041-bib-0007){ref-type="ref"}

The affinities of PhK for phosphorylase *b* and ATP were evaluated by changing the concentration of the specific substrate. Michaelis constants (*K* ~m~) were determined by double reciprocal plotting of the substrate concentration and the reaction velocity. The thermal stability and affinity results were compared with those of three adult controls.

4. RESULTS {#jmd212041-sec-0008}
==========

4.1. Gene panel analysis {#jmd212041-sec-0009}
------------------------

The *PHKA2* variant c.2972G\>C (p.G991A) (NM_000292.2) was detected (rs761088614) in the patient. The patient\'s younger brother did not have this variant, and his mother had this variant in the heterozygous state, which was confirmed by Sanger sequencing. In silico analyses were performed by MutationTaster, PolyPhen‐2, PROVEAN, and SIFT. Each result was disease causing, probably damaging with a score of 0.989, deleterious, and damaging, respectively. Based on the American College of Medical Genetics and Genomics (ACMG) recommendations,[8](#jmd212041-bib-0008){ref-type="ref"} the pathogenicity of this variant meets the criteria of PP3 and PP4.

4.2. Enzyme assay {#jmd212041-sec-0010}
-----------------

First, we evaluated the activity and the thermal stability of the variant PhK in erythrocytes from the patient. The activity of the variant PhK in the patient\'s erythrocytes was not significantly different from those of the three controls, as shown in Table [2](#jmd212041-tbl-0002){ref-type="table"}. However, the variant PhK was less stable than controls at a temperature of 45 °C (Figure [1](#jmd212041-fig-0001){ref-type="fig"}). Second, we evaluated the affinity of the variant PhK for phosphorylase *b* and ATP. The *K* ~m~ values of the patient\'s PhK with respect to phosphorylase *b* were 75.3 Units/mL, which was higher than those of three controls (mean 35.6 Units/mL, SD 5.84 Units/mL). The *K* ~m~ value of the patient\'s PhK against ATP did not differ from those of controls (data not shown).

###### 

Results of the enzyme activity assay using blood cells

                       Control 1   Control 2   Case   Disease control
  -------------------- ----------- ----------- ------ -----------------
  PhK (nmol/min/gHb)   8.5         13.8        8.1    0.8

![Variant PhK was less stable than putative wild‐type PhK (extracted from erythrocytes of three healthy adults) at a temperature of 45°C. The remaining activity of variant PhK was about 50%‐60% of that of wild‐type PhK after 5‐10 min of incubation](JMD2-48-15-g001){#jmd212041-fig-0001}

5. DISCUSSION {#jmd212041-sec-0011}
=============

We describe the case of a boy who suffered from frequent KH but did not have hepatomegaly or elevated liver enzyme levels. This patient sometimes developed hypoglycemia after overnight fasting. This was confirmed by a fasting test in which the patient developed hypoglycemia after 14.5 hours of fasting. This fasting time was too short to induce ketoacidosis because the total ketone body level was about 1.4 mM, whereas the free fatty acid level was induced to about 3 mM. Consequently, we suspected that the patient might have problems with glycogenolysis rather than with gluconeogenesis, fatty acid metabolism, or ketone body metabolism. The gene panel analysis identified a rare *PHKA2* variant, p.G991A. We considered this variant to be the likely cause of the patient\'s KH.

Recently, Brown et al.[1](#jmd212041-bib-0001){ref-type="ref"} found that 20 KH patients had variants in genes causing GSDs (including 4 of type 0, 2 of typeVI, 12 of type IXa, 1 of type IXb, and 1 of type IXc) by performing Sanger sequencing on five genes (*GYS2*, *PYGL*, *PHKA2*, *PHKB*, and *PHKG2*) of 164 KH patients without hepatomegaly.[1](#jmd212041-bib-0001){ref-type="ref"} This finding was surprising, because most clinicians do not suspect GSDs unless patients have enlarged livers or present with elevated liver enzyme levels. This unexpected result of Brown et al. led us to consider that the p.G991A variant of *PHKA2* might be the causative factor of KH in our patient. Although the PhK activity in the patient\'s erythrocyte lysate was within the normal range, we further analyzed the thermal stability of PhK and its *K* ~m~. This revealed that the patient\'s PhK was thermally unstable and had a higher *K* ~m~ value than that of the controls.

The p.G991A variant of *PHKA2* is rare. The allele frequency of this variant (rs761088614) is 4.57 × 10^−5^ in the worldwide population (retrieved on November 17, 2018, from: <http://exac.broadinstitute.org/>variant/X‐18919658‐C‐G). According to a Japanese database (retrieved on November 17, 2018, from: [http://www.hgvd.genome.med.kyoto‐u.ac.jp/cgi‐bin/searchBydbsnp.cgi](http://www.hgvd.genome.med.kyoto-u.ac.jp/cgi-bin/searchBydbsnp.cgi)), the allele frequency of this variant in Japan is 5.15 × 10^−3^, which is much higher than that in the global population. This means that about 1 in 200 males in Japan have this variant. The prevalence of KH has not been reported from Japan or from many other countries, but the prevalence of this variant in Japanese males likely reflects the prevalence of KH in Japan. If KH is caused by a *PHKA2* variant in most patients, the treatment strategy for such KH patients should be similar to the treatment for GSD type IXa.

One limitation of the current study is that it concerns a single case only, and our experience is still limited. However, we carried out some preliminary analyses of the presence of the p.G991A variant in KH patients in Japan and found that several KH patients did possess the variant (unpublished data, Fukao et al.). Further research will be necessary to investigate whether this variant is the most important genetic factor causing KH in Japan.

6. CONCLUSION {#jmd212041-sec-0012}
=============

A rare p.G991A variant of *PHKA2* was identified in a Japanese KH patient. The variant resulted in some functional abnormalities and may have been the cause of KH in this patient.
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